Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Johnson Einstein, M.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
Yale University, New Haven, CTBS05/2007Biology
Tufts University School of Medicine, Boston, MAMD05/2011
Tufts Medical Center, Boston, MA06/2014Internal Medicine Residency
Beth Israel Deaconess Medical Center, Boston, MA06/2017Hematology/Oncology Fellowship

Overview
I am an academic medical oncologist specializing in genitourinary (GU) cancers. I care for patients with prostate, bladder, kidney, and testicular cancer. My clinical activities include providing direct patient care and consultation during three-to-four half-day clinics a week and four weeks a year on the inpatient oncology ward and hematology/oncology consult services, during which time I also teach and supervise residents and fellows. In addition, I spend approximately half of my time on genitourinary oncology research, particularly focusing on immunotherapy and targeted approaches in prostate, bladder, and kidney cancers, with support from the Prostate Cancer Foundation, DoD, BIDMC, and industry partners. I am interested in clinical trial development, serving as overall Principal Investigator (PI) and site PI of several Dana-Farber/Harvard Cancer Center (DF/HCC) clinical trials that investigate immune-based and targeted therapies for GU cancers. In addition, I am the Director of GU Oncology Clinical Research for the Beth Israel-Lahey Health network. I conduct translational research as PI of the DF/HCC GU Rapid Autopsy program, a component of the Pathology core of the DF/HCC Prostate SPORE proposal. I am first author of the American Society of Clinical Oncology Self-Evaluation Program GU chapter 7th edition and ongoing reviewer. Finally, I have developed tools to improve quality of life, physician communication, and end-of-life decision-making, especially as it relates to patients with GU cancers.

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. P20-CA233255 Developmental Research Project (Steven Balk and David Einstein) Mar 31, 2019 - Mar 31, 2020
    Genomic Features of Immunogenic Prostate Cancer in African-American Patients
    Role: Co-Investigator
  2. Bridge Grant (Steven Balk, David Einstein, & Michael Yaffe) Mar 1, 2019 - Feb 28, 2021
    Bridge Project (Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center
    Optimizing Plk1 Therapeutics for Clinical Translation
  3. Challenge Award (Steven Balk) Jan 1, 2019 - Jan 1, 2021
    Prostate Cancer Foundation
    Identifying and Targeting Immunogenic Prostate Cancer at High Risk for Lethal Metastatic Progression
    Role: Co-Investigator
  4. W81XWH-17-1-0350 (David J Einstein) Aug 1, 2017 - Jul 30, 2021
    Congressionally Directed Medical Research Programs (CDMRP) Prostate Cancer Research Program (PCRP)
    Prognostic Biomarkers in Active Surveillance: Parsing Risk in Early-Stage Prostate Cancer

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Quinn Z, Leiby B, Sonpavde G, Choudhury AD, Sweeney C, Einstein D, Szmulewitz R, Sartor O, Knudsen K, Yang ES, Kelly WK. Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate Resistant Prostate Cancer. Clin Cancer Res. 2022 Nov 02. PMID: 36321991.
    Citations:    Fields:    
  2. Patell R, Miller E, Einstein D, Dodge LE, Halleck J, Buss MK. Does Use of Information Sources Outside the Treating Oncologist Influence Patient Decision-Making in Patients Receiving Non-Curative Intent Therapy for Advanced Cancer. Am J Hosp Palliat Care. 2022 Oct 17; 10499091221134531. PMID: 36252248.
    Citations:    Fields:    
  3. Viray H, McDermott DF, Einstein DJ. Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval. Expert Rev Anticancer Ther. 2022 07; 22(7):695-702. PMID: 35698870.
    Citations:    Fields:    Translation:Humans
  4. Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein M, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol. 2022 09 01; 40(25):2913-2923. PMID: 35442713; PMCID: PMC9426835.
    Citations: 3     Fields:    
  5. Ma F, Arai S, Wang K, Calagua C, Yuan AR, Poluben L, Gu Z, Russo JW, Einstein DJ, Ye H, He MX, Liu Y, Van Allen E, Sowalsky AG, Bhasin MK, Yuan X, Balk SP. Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer. Cancer Res. 2022 04 15; 82(8):1518-1533. PMID: 35131873; PMCID: PMC9018564.
    Citations: 1     Fields:    Translation:HumansCells
  6. Sentana-Lledo D, Sartor O, Balk SP, Einstein DJ. Immune mechanisms behind prostate cancer in men of African ancestry: A review. Prostate. 2022 06; 82(8):883-893. PMID: 35254710.
    Citations:    Fields:    Translation:HumansCells
  7. Einstein DJ, Arai S, Calagua C, Xie F, Voznesensky O, Capaldo BJ, Luffman C, Hecht JL, Balk SP, Sowalsky AG, Russo JW. Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors. JCO Precis Oncol. 2021; 5. PMID: 34568716; PMCID: PMC8457789.
    Citations: 3     Fields:    Translation:Humans
  8. Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, Balk SP, Einstein DJ. A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clin Cancer Res. 2021 09 01; 27(17):4836-4847. PMID: 34168052; PMCID: PMC8416924.
    Citations: 2     Fields:    Translation:HumansCells
  9. Cole SM, Sarangi S, Einstein D, McMasters M, Alterman R, Bruce J, Hertan L, Shih HA, Wong ET. Parkinsonism reversed from treatment of pineal non-germinomatous germ cell tumor. Surg Neurol Int. 2021; 12:237. PMID: 34221568; PMCID: PMC8248242.
    Citations:    
  10. Santopietro AL, Einstein D, Bellmunt J. Advances in the management of urothelial carcinoma: is immunotherapy the answer? Expert Opin Pharmacother. 2021 Sep; 22(13):1743-1759. PMID: 33905290.
    Citations: 1     Fields:    Translation:Humans
  11. Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, Qiu X, Cañadas I, Roehle K, Heckler M, Calagua C, Ye H, Pantelidou C, Galbo P, Panja S, Mitrofanova A, Wilkinson S, Whitlock NC, Trostel SY, Hamid AA, Kibel AS, Barbie DA, Choudhury AD, Pomerantz MM, Sweeney CJ, Long HW, Einstein DJ, Shapiro GI, Dougan SK, Sowalsky AG, He HH, Freedman ML, Balk SP, Loda M, Labbé DP, Olson BM, Ellis L. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021 04; 2(4):444-456. PMID: 33899001; PMCID: PMC8061902.
    Citations: 30     Translation:HumansCells
  12. McKay RR, Xie W, Ye H, Fennessy FM, Zhang Z, Lis R, Calagua C, Rathkopf D, Laudone VP, Bubley GJ, Einstein DJ, Chang PK, Wagner AA, Parsons JK, Preston MA, Kilbridge K, Chang SL, Choudhury AD, Pomerantz MM, Trinh QD, Kibel AS, Taplin ME. Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. J Urol. 2021 07; 206(1):80-87. PMID: 33683939.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  13. Patell R, Einstein D, Miller E, Dodge L, Halleck J, Buss M. Patient Perceptions of Treatment Benefit and Toxicity in Advanced Cancer: A Prospective Cross-Sectional Study. JCO Oncol Pract. 2021 02; 17(2):e119-e129. PMID: 33444075.
    Citations: 1     Fields:    Translation:Humans
  14. Bilusic M, Einstein DJ, Karzai FH, Dahut WL, Gulley JL, Aragon-Ching JB, Madan RA. The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. Urol Clin North Am. 2020 Nov; 47(4):457-467. PMID: 33008496; PMCID: PMC8177734.
    Citations:    Fields:    Translation:Humans
  15. Garnick MB, Einstein DJ. EDITORIAL COMMENT. Urology. 2020 11; 145:118-119. PMID: 33167168.
    Citations:    Fields:    
  16. Halbert B, Einstein DJ. Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers. Urology. 2021 01; 147:119-126. PMID: 33137348.
    Citations: 7     Fields:    Translation:Humans
  17. Einstein DJ, Liang N, Malhotra M, Aleshin A, Moshkevich S, Billings PR, Pectasides E. Assessment of Molecular Remission in Oligometastatic Esophageal Cancer With a Personalized Circulating Tumor DNA Assay. JCO Precis Oncol. 2020 Nov; 4:239-243. PMID: 35050735.
    Citations:    Fields:    
  18. Awasthi S, Berglund A, Abraham-Miranda J, Rounbehler RJ, Kensler K, Serna A, Vidal A, You S, Freeman MR, Davicioni E, Liu Y, Karnes RJ, Klein EA, Den RB, Trock BJ, Campbell JD, Einstein DJ, Gupta R, Balk S, Lal P, Park JY, Cleveland JL, Rebbeck TR, Freedland SJ, Yamoah K. Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clin Cancer Res. 2021 01 01; 27(1):320-329. PMID: 33037017; PMCID: PMC8042600.
    Citations: 16     Fields:    Translation:Humans
  19. Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, Wilkinson S, Carrabba NV, Atway R, Shema S, Lake R, Sweet AR, Einstein DJ, Karzai F, Gulley JL, Chang P, Bubley GJ, Balk SP, Ye H, Sowalsky AG. Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. JCO Precis Oncol. 2019; 3. PMID: 31528835.
    Citations: 13     Fields:    
  20. Garnick MB, Einstein DJ. EDITORIAL COMMENT. Urology. 2019 09; 131:182-183. PMID: 31451158.
    Citations: 1     Fields:    Translation:Humans
  21. Einstein DJ, Arai S, Balk SP. Targeting the androgen receptor and overcoming resistance in prostate cancer. Curr Opin Oncol. 2019 05; 31(3):175-182. PMID: 30893145; PMCID: PMC6465077.
    Citations: 11     Fields:    Translation:Humans
  22. Einstein DJ, Patil D, Chipman J, Regan MM, Davis K, Crociani CM, Wagner AA, Sanda MG, Chang P. Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer. Urology. 2019 05; 127:53-60. PMID: 30790648.
    Citations: 2     Fields:    Translation:Humans
  23. Einstein DJ, Sonpavde G. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer. Curr Treat Options Oncol. 2019 02 11; 20(2):12. PMID: 30741358.
    Citations: 1     Fields:    Translation:Humans
  24. Russo JW, Liu X, Ye H, Calagua C, Chen S, Voznesensky O, Condulis J, Ma F, Taplin ME, Einstein DJ, Balk SP, Chen S. Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett. 2018 12 01; 438:97-104. PMID: 30217568; PMCID: PMC6186500.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  25. Einstein DJ. Compassion and Compassionate Use. J Clin Oncol. 2018 10 10; 36(29):2969-2971. PMID: 30156981; PMCID: PMC7098837.
    Citations:    Fields:    Translation:Humans
  26. Einstein DJ, McDermott DF. Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer. Clin Adv Hematol Oncol. 2017 Jun; 15(6):478-488. PMID: 28749908.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  27. Einstein DJ, DeSanto-Madeya S, Gregas M, Lynch J, McDermott DF, Buss MK. Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies. J Oncol Pract. 2017 09; 13(9):e729-e737. PMID: 28562197.
    Citations: 9     Fields:    Translation:Humans
  28. Mathew P, Einstein DJ, Ladin K. Against "Healthy Paternalism" at the End of Life-Reply. JAMA Oncol. 2016 Jun 01; 2(6):833. PMID: 27281630.
    Citations:    Fields:    Translation:Humans
  29. Einstein DJ, Ladin K, Mathew P. The Ethical Imperative of Healthy Paternalism in Advance Directive Discussions at the End of Life. JAMA Oncol. 2016 Apr; 2(4):429-30. PMID: 26914544.
    Citations: 3     Fields:    Translation:Humans
  30. Einstein DJ, Trowbridge RL, Rencic J. A Problematic Palsy: An Exercise in Clinical Reasoning. J Gen Intern Med. 2015 Jul; 30(7):1029-33. PMID: 25743429.
    Citations: 2     Fields:    Translation:Humans
  31. Einstein DJ, Einstein KL, Mathew P. Dying for Advice: Code Status Discussions between Resident Physicians and Patients with Advanced Cancer--A National Survey. J Palliat Med. 2015 Jun; 18(6):535-41. PMID: 25984641.
    Citations: 8     Fields:    Translation:Humans
  32. Einstein DJ. Knot. Ann Intern Med. 2012 Sep 04; 157(5):381-2. PMID: 22944877.
    Citations:    Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Einstein's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (125)
Explore
_
Co-Authors (44)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.